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Investigation• of pituitary adenylate cyclaseAQ1
activating polypeptide in human gynecological
and other biological fluids by usingMALDI TOF
mass spectrometry†
R. Brubel,a D. Reglodi,a E. Jambor,b M. Koppan,a,c A. Varnagy,c Zs. Biro,d
P. Kiss,a V. Gaal,d A. Matkovits,a J. Farkas,a A. Lubics,a J. Bodis,c Cs. Bay,c
B. Veszpremi,c A. Tamas,a J. Nemethe and Laszlo Markb∗
Pituitary adenylate cyclase activating polypeptide (PACAP) is a multifunctional and pleiotropic neuropeptide. PACAP has
diverse effects in the endocrine system, among others, it plays important roles in oogenesis, implantation and development of
thenervous system.However, it is not knownwhether PACAP is present in thefluids of thehuman reproductive organs. The aim
of the present study was to determine, by means of mass spectrometry and radioimmunoassay, whether PACAP is present in
human amniotic fluid, ovarian follicular fluid and cervico-vaginal fluid. Samples were obtained from healthy adult volunteers.
Our MALDI TOF and MALDI TOF/TOF spectrometry results show that PACAP38 is present in all of the follicular fluid samples,
and PACAP-like immonoreactivity was also measured by radioimmunoassay. However, we did not find the characteristic peak
representing the unmodified 38 amino acid form of the peptide in normal cervico-vaginal smear and amniotic fluid samples.
Furthermore, we analyzed other body fluids for comparison, such as human nasal fluid, saliva and aqueous humor. PACAP
was not found in these latter samples. In summary, the present study provides evidence for the presence of PACAP in human
follicular fluid, suggesting a role in oocyte function, but determination of the exact physiological significance awaits further
investigation. Copyright c© 2011 JohnWiley & Sons, Ltd.
Keywords: cervico-vaginal fluid; amniotic fluid; follicular fluid; nasal fluid; saliva; aqueous humor;mass spectrometry; radioimmunoassay
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Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP) was
originally isolated from the hypothalamus, based on its cAMP-
increasing effect in pituitary cells.[1,2] PACAP occurs in two amino
acid forms: PACAP38 and PACAP27, with the 38 amino acids
form being predominant in human tissues.[1–5] Although the last
two decades since its discovery have revealed that PACAP is much
more than ‘just’ ahypothalamo/hypophyseal peptide, its functions
played in the endocrine system are still in focus of research.[3–6]
Regarding reproductive endocrinology, PACAP has been shown
to play a role in the regulation of gonadotropin secretion,[3,7,8]
fertility, receptivity, implantation, reproductive behavior[9–11] and
placental functions.[12] Furthermore, PACAPdelayspuberty[13] and
reduces follicular apoptosis in the ovary.[14]
Mass spectrometry (MS) is a high-throughput technique to ana-
lyze peptide/protein composition of biological fluids.[15] We have
previously shown the presence of PACAP in human serum and hu-
man breast milk using matrix-assisted laser desorption/ionization
time-of-flight (MALDI TOF) and matrix-assisted laser desorp-
tion/ionization tandem time-of-flight (MALDI TOF/TOF) MS.[16]
This technique provides a powerful tool for investigating other
biological samples and fluids as well. Peptide profiling of bio-
logical samples has become increasingly important in search for
biomarkers and in investigation of differences between normal
and pathological fluids.[17] Given the importance of endogenous
PACAP in reproductive physiology, the first aim of the present
study was to investigate the occurrence of PACAP in human fluids
of the reproductive system.
Ovarian follicular fluid is the product of granulosa and theca
cells as well as a plasma filtrate through the wall of the developing
follicle.[17] It functions as a culture medium for the developing
oocyte. Since PACAP has been shown to play a role in follicular
development,[14,18,19] it was of interest to examine whether the
peptide occurs in the follicular fluidusingMALDI TOF andTOF/TOF
MS, and if present, to detect its levels in follicular fluid samples
using radioimmunoassay (RIA).
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Amniotic fluid is partially a plasma filtrate and a product of
the fetal epithelial cells. Its integrity is essential for the normal
development of the fetus.[15,19] The diagnostic value of amniotic
fluid has long been appreciated. The levels of several proteins,
biomarkers for genetic malformations, have been investigated in
detail. It is not knownwhether PACAP occurs in the amniotic fluid.
Cervico-vaginal fluid originates from the vaginal wall itself, and
from cervical mucus and salpingo-uterine fluid.[21,22] Proteomic
analysis has revealed dozens of proteins and peptides that play
important roles in thedefensemechanismsexertedby the cervico-
vaginal fluid. Since PACAP has well-known anti-inflammatory
effects, we aimed to study the possible occurrence of PACAP
in the cervico-vaginal fluid.
In addition to fluids of the reproductive system, we analyzed
other body fluids, like saliva, nasal fluid and aqueous humor.
Human saliva is secreted from multiple salivary glands including
parotid, submandibular, sublingual and other minor glands lying
in the oral mucosa. The presence of PACAP has been shown in
the main salivary glands of rodents.[23–25] It has been shown that
PACAP enhances salivary flow and protein output and inhibits
Ca2+ channels in the salivary glands.[24,26,27] Based on these
observations, we aimed to examine whether PACAP is found
also in the product of the salivary glands.
Human nasal fluid is produced by the epithelium of the nasal
cavity and the underlying secretory glands. Proteomic analysis
has identified 83 proteins in the nasal mucus of healthy adult
volunteers using two-dimensional gel electrophoresis, MALDI-
TOF and RPLC.[28] The presence of PACAP-containing nerve fibers
has already been identified in the nasal mucosa, and PACAP has
been shown to increase nasal airway resistance.[29] In addition, one
study has suggested that PACAP could be a candidate biomarker
of chronic sinusitis.[30] Therefore, we tested whether PACAP is
present in the nasal mucosal fluid.
Human aqueous humor is a plasma filtrate from the blood
vessels of the ciliary processes. It maintains intraocular pressure
andplays an important role in the pathogenesis of ocular diseases.
VIP, the peptide with closest structural similarity to PACAP, has
been identified in human aqueous humor, showing significant
differences between glaucoma and cataract patients.[30] However,
it is not known whether PACAP occurs in this fluid. Therefore, the
aim of our present study was to identify the presence of PACAP in
human aqueous humor.
In summary, the aim of the present study was to determine the
presence of PACAP in fluids of the female reproductive system,
such as follicular and amniotic fluids and cervico-vaginal smear,
and in further biological samples, such as saliva, nasal fluid and
aqueous humor.
Materials andMethods
Biological samples
Human biological samples were collected according to a proto-
col approved by the institutional ethic committee (3117/2008,
3610/2009), during ophthalmological surgery or routine gyneco-
logicalexaminations,withoutextra intervention.Patientsprovided
written approval of the sample collection in all cases. The samples
were further processed for MS analysis based on modifications
of earlier descriptions.[16] The peptidase inhibitor aprotinin was
added to all samples (30 µl/ml), except for the cervico-vaginal
fluid, nasal fluid and saliva on filter paper.
Follicular fluid was collected from female volunteers (aged
between 20 and 35, n = 40) by follicular puncture after
controlledovarianhyperstimulationduring the in vitro fertilization
procedure.
Amniotic fluid specimens were collected at the 16th week
of gestation from volunteering pregnant females undergoing
amniocentesis as a prenatal diagnostic tool due to maternal age
(age over 35 years, n = 25).
Cervico-vaginal fluid samples were collected from female
volunteers in the progesterone phase of the cycle (aged between
25 and 35, n = 10) by the application of sterile filter paper strips
(Schirmer paper) during colposcopic examination. Human nasal
fluid (aged between 20 and 40, n = 10) and saliva (aged between
20 and 40, n = 10) were also collected by the application of sterile
filter paper strips (Schirmer paper) from healthy volunteers.
Human aqueous humor was collected from volunteers (aged
between 60 and 85, n = 10) during cataract surgery.
Sample preparation
A100-µl of the follicularfluidsamplewascentrifugedat10000 rpm
for 5 min, followed by the addition of 10 µl of 72% trichloroacetic
acid and 100 µl of H2O2 to 90 µl of the supernatant. The samples
were centrifuged at 13 000 rpm for 10 min after precipitation. The
amniotic fluid (200 µl) was centrifuged at 10 000 rpm for 5 min.
The supernatant (100 µl) was acidified by 100 µl 1% trifluoroacetic
acid (TFA) and then centrifuged at 13 000 rpm for 10 min.
The solutions from the above-described samples were desalted
and cleaned using 0.1% TFA solution with ZipTip18 pipette tips
(Millipore Kft., Hungary). The purified proteins and peptides
were eluted directly onto the MALDI target plate (MTP 384
massive target T, Bruker Daltonics, Bremen, Germany) by 3 µl
of acetonitrile/0.1% TFA (50 : 50, v/v) solution by mixing 1 µl of a
saturatedmatrix solution, prepared freshly every day bydissolving
a-cyano-4-hydroxycinnamic acid in acetonitrile/0.1% TFA (1 : 2,
v/v).
The cervico-vaginal fluid, human nasal fluid and saliva were
dissolved by using 100 µl of acetonitrile–0.1% TFA (5 : 95, v/v)
mixture in an ultrasonic bath at 5 min. The samples, including
the human aqueous humor, were loaded onto the target plate
(MTP 384 massive target T, Bruker Daltonics) directly by mixing
1–1 µl of each solution with the same volume of a saturated
matrix solution, prepared freshly every day by dissolving a-cyano-
4-hydroxycinnamic acid in acetonitrile/0.1% TFA (1 : 2, v/v).
Mass spectrometry
IdentificationofPACAP38wasperformedwithMALDITOF/TOFMS.
Briefly, the mass spectrometer used in this work was an Autoflex
II TOF/TOF (Bruker Daltonics) operated in the linear detector for
MALDI TOF or LIFT mode for high-energy collision-induced decay
MALDI TOF/TOF with an automated mode using the FlexControl
software. The ions were accelerated under delayed extraction
conditions (200 ns) in positive ion mode with an acceleration
voltageof 20.00 kV. The instrumentuses a 337-nmpulsednitrogen
laser, model MNL-205MC (LTB Lasertechnik Berlin GmbH, Berlen,
Germany). External calibration was performed in each case using
Bruker Peptide Calibration Standard (#206 195 Peptide Calibration
Standard, Bruker Daltonics). Protein masses were acquired with a
range of m/z 1000 to 10 000. Each spectrum was proceeded by
accumulating data from 200 consecutive laser shots for standard
PACAP38 solution and 1000 for amniotic, follicular, cervico-
vaginal, nasal fluid, saliva and aqueous humor samples. The Bruker
wileyonlinelibrary.com/journal/jms Copyright c© 2011 John Wiley & Sons, Ltd. J. Mass. Spectrom. 2011, 46, 0
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FlexControl 2.4 software was used to operate the instrument and
the Bruker Flexanalysis 2.4 software for spectrum evaluation.
Radioimmunoassay
Follicular fluidwas collectedasdescribedabove. The sampleswere
weighed and centrifuged (12 000 rpm, 4 ◦C, 30 min), and the su-
pernatant was further processed for RIA analysis of PACAP38-like
immunoreactivity, as previously described.[16] Briefly, the condi-
tions were as follows: antiserum: PACAP38: ‘88 111-3’ (working
dilution 1 : 10 000), tracer: mono-125I-labeled ovine PACAP24-38
prepared in our laboratory (5000 cpm/tube), standard: ovine
PACAP38 was used as a RIA standard ranging from 0 to 1000
fmol/ml, buffer: the assay was prepared in 1 ml of 0.05 mol/l (pH
7.4) phosphate buffer containing 0.1 mol/l sodium chloride, 0.25%
(w/v) BSA and 0.05% (w/v) sodium azide. Incubation time: 48–72 h
incubation at 4 ◦C. Separation solution: charcoal/dextran/milk
powder (10 : 1 : 0.5 g in 100 ml distilled water).
Results
Mass spectrometry
The sample preparation procedure optimized for each biological
fluid was suitable for measuring and identifying low molecular
weight peptides by MS. Based on our previous and current
results, sensitive and reproducible identification of PACAP38 can
be carried out using linear MALDI TOF MS. The characteristic
peak of PACAP38 is m/z 4536.0, as verified in the PACAP
standard solutions (Fig. 1(a)). The collision-induced decay MALDI
TOF/TOF fragmentation of PACAP38 standard yielded mainly y
fragment ions of the PACAP38parent ion (m/z 4536.0; Fig. 1(b)).[16]
MS analysis revealed that PACAP38 was present in all of the
stimulated ovarian follicular fluid samples. The mass spectrum
of a representative positive follicular fluid sample with the
characteristic PACAP38 peak is shown in Fig. 1(c). For further
evidenceof thepresenceof PACAP38 in the follicular fluid samples,
the collision-induced decay MALDI TOF/TOF fragmentation was
carried out in each case. This yielded similar fragments as found
in PACAP38 standard (Fig. 1(d)). On the contrary, MS results could
not prove the presence of the unmodified PACAP38 in any of the
amniotic fluid, cervico-vaginal fluid, nasal fluid, human saliva or
aqueoushumorsamples (fromall thesespectrawithno identifiable
PACAP peak, only one example is shown in Fig. 1(e)). The signal-
to-noise ratios were also calculated in order to provide additional
piece of evidence for the specificity of the peak representing
PACAP38. These data are shown in Table 1.
Radioimmunoassay
PACAP38-like immunoreactivity was detected in the follicular
fluid using a specific and sensitive RIA method. Average
level of PACAP38 in follicular fluid samples (n = 24) was
161.1 ± 20.3 fmol/ml.
Discussion
The present study provided mass spectrometric evidence that
PACAP occurs in the ovarian follicular fluid, while it is absent in
the amniotic fluid, in the cervico-vaginal smear, nasal fluid, human
saliva and in the aqueous humor.
In this study, we found the presence of PACAP38 in ovarian
follicular fluid, obtained from 40 stimulated female patients.
Here, all of the samples contained PACAP38. The follicular fluid
serves as a culture medium for the developing oocyte, and it
is important for the morphological and functional integrity for
the germ cell development. PACAP has been shown to have
several functions in follicular development. PACAP is expressed
stage-specifically in granulosa cells of large mature follicles
before ovulation, but weaker expression has also been shown
in the wall of immature antral and pre-antral follicles.[19,32,33]
PACAP receptors have also been demonstrated in developing
follicles.[34–36] Both PACAP and PAC1 receptors have been
demonstrated in the corpus luteum.[37] The PACAP found in
the follicular fluid may derive from granulose and/or theca
cells. The peptide is thought to play a role in primordial germ
cell proliferation,[38] cyclic recruitment of immature follicles,[32]
follicular apoptosis,[14,36] meioticmaturation of the oocytes[18] and
ovarian hormone and enzyme production.[39–42] The finding that
PACAP occurs in all of the ovarian follicular fluid samples indicates
an important biological role for PACAP in this culture medium for
the developing oocytes, the exact determination of which awaits
further investigation. In addition, RIA measurements provided
evidence for the presence of PACAP-like immunoreactivity in the
follicular fluid samples. The variation in the immunoreactivity may
be due to different physiological status or pathological conditions,
the detailed analysis of which is beyond the scope of the present
paper, but it could serve as abasis for further studies in the attempt
to find correlation between pathological conditions, and/or the
number of oocytes and PACAP levels.
Inamniotic, cervico-vaginal,nasalfluid, salivaand in theaqueous
humor we could not detect unmodified PACAP38 by MS. This
could possibly be due either to the complete lack of PACAP in the
samples, or levels below detection limit. The rapid digestion can
be excluded as explanation, sincewe added peptidase inhibitor to
the samples. It is also conceivable that in some samples PACAP, or
its fragments, would occur in a modified form, the determination
of which would require further experiments. Another possibility
is that the different biological fluids exhibit different qualitative
and quantitative composition. This could also be reflected in
suppression effects, which is often observed in MALDI spectra
of complex protein–peptide mixtures. The lack of PACAP found
in the present study does not necessarily exclude the possibility
that PACAP could be found under pathological circumstances.
However, based on the present findings, we can conclude that
under physiological circumstances PACAP, in its original form, is
not present in the amniotic, cervico-vaginal, nasal fluid, saliva or
in the aqueous humor.
In summary, our present data show, for the first time, the
presence of PACAP38 in ovarian follicular fluid. The exact
physiological role of PACAP in this biological fluid is not yet
known, but based on the effects of PACAP in oogenesis, as well
as in ovarian hormonal secretion, the peptide present in follicular
fluid might play a role in oocyte function.
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Figure 1. (a) MALDI TOF spectrum of PACAP38 in positive ion mode using linear detection indicating the protonated quasimolecular ion peak at m/z
4536.0 in PACAP38 standard. (b) Collision-induced decay fragmentation of them/z 4536 peak as a parent ion with the main fragment y ions in PACAP38
standard. (c) MALDI TOF spectrum of follicular fluid samples. The peptide peak characteristic for PACAP38 (m/z 4536.0) could be identified in all of
the samples. (d) Collision-induced decay fragmentation of the m/z 4536 peak as a parent ion with the main fragment y ions in follicular fluid samples.
(e) Characteristic MALDI TOF spectrum of human saliva samples in positive ion mode using linear detection, where the characteristic peak of PACAP38
(m/z 4536.0) could not be found. Insets show the closer view ofm/z range where the characteristic PACAP38 peak could be found.
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Table 1. The calculated signal-to-noise ratios of the samples
Sample Peak intensity (m/z 4536) Noise intensity S/N
PACAP 38 standard 2130 35 61
Follicular fluid 920 45 20
Saliva 43 40 1
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